Abstract
The increasing risk from viral outbreaks such as the ongoing COVID-19 pandemic exacerbates the need for rapid, affordable and sensitive methods for virus detection, identification and quantification; however, existing methods for detecting virus particles in biological samples usually depend on multistep protocols that take considerable time to yield a result. Here, we introduce a rapid fluorescence in situ hybridization (FISH) protocol capable of detecting influenza virus, avian infectious bronchitis virus and SARS-CoV-2 specifically and quantitatively in approximately 20 minutes, in both virus cultures and combined throat and nasal swabs without previous purification. This fast and facile workflow is applicable to a wide range of enveloped viruses and can be adapted both as a lab technique and a future diagnostic tool.
Competing Interest Statement
The work was carried out using a wide-field microscope from Oxford Nanoimaging, a company in which A.N.K. is a co-founder and shareholder.
Funding Statement
This research was supported by a Royal Society Dorothy Hodgkin Research Fellowship DKR00620 (N.C.R.), the University of Oxford COVID-19 Research Response Fund (N.C.R and A.N.K.), a BBSRC-funded studentship (N.S.), BBSRC grant BB/V001868/1 (C.H., N.C.R. and A.N.K.) and Wellcome Trust grant 110164/Z/15/Z (A.N.K.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Experiments using throat swab material were performed in accordance with the Declaration of Helsinki and approved by the Medical Sciences Interdivisional Research Ethics Committee of the University of Oxford (R76273/RE001). Informed consent was obtained from the throat swab donor.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data will be available upon request.
